Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

27.5.21

News

Innosuisse innovation project starting May 2021

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

2.11.23

News

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juvic Inc.

24.10.24

News

Topadur Pharma AG announces CEO change

The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Innosuisse innovation project starting May 2021

TOPADUR, Yonsei University and Juvic Inc. grant awarded

Topadur Pharma AG announces CEO change

About us

Approach

Disease Areas

Investors

Contact